B. Riley initiated coverage of Palisade Bio (PALI) with a Buy rating and $7 price target The company is developing PALI-2108, a pro-drug PDE4 B/D inhibitor, incorporating tissue-specific activation for the treatment of ulcerative colitis and fibrostenotic Crohn’s disease, the analyst tells investors in a research note. Riley views PALI-2108 as an attractive option in the inflammatory and fibrotic disease space.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio announces equity investment from Crohn’s & Colitis Foundation
- Palisade Bio granted Japanese patent covering PALI-2108
- Palisade Bio initiated with a Buy at Clear Street
- Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
- Palisade Bio initiated with an Overweight at Piper Sandler